Get the Stockscreener App
0.817
1.77%
0.0113
Silexion Therapeutics Corp stock is traded at $0.817, with a volume of 84,528.
It is up +1.77% in the last 24 hours and down -10.48% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$0.8057
Open:
$0.8491
24h Volume:
84,528
Relative Volume:
0.05
Market Cap:
$8.89M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.035
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
-10.07%
1M Performance:
-10.48%
6M Performance:
-61.68%
1Y Performance:
+0.00%
1-Day Range:
$0.8001
$0.85
1-Week Range:
$0.80
$0.9299
52-Week Range:
$0.575
$23.13
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.8203 | 8.89M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.32 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.79 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
539.50 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.38 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors - MSN
Silexion Therapeutics Requests Hearing on Nasdaq Delisting - TipRanks
Silexion Therapeutics announces preclinical results on SIL204 - Yahoo Finance
Silexion’s SIL-204 shows promise in pancreatic, colorectal and lung cancer cell lines - BioWorld MedTech
Silexion reports breakthrough in KRAS-driven cancer therapy By Investing.com - Investing.com South Africa
Silexion reports breakthrough in KRAS-driven cancer therapy - Investing.com Australia
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers - The Manila Times
Silexion Therapeutics Announces Groundbreaking Preclinical - GlobeNewswire
Revolutionary Cancer Drug Shows 90% Inhibition Rate Against Pancreatic, Lung, and Colorectal Cancers in New Study - Stock Titan
Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World
Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView
Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq
Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com
Silexion Completes Key Preclinical Studies for SIL204 - TipRanks
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - The Manila Times
Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire
Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan
Form 424B3 Silexion Therapeutics - StreetInsider
Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News
Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -
Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa
SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks
Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia
Silexion Therapeutics enters collaboration with Catalent - TipRanks
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World
Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com
Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire
Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Expands SIL204 Development Plan - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com
Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener
Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan
Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World
Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN
Silexion announces completion of expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):